Madrigal Pharmaceuticals, Inc. (MDGL) Institutional Ownership & Insider Trading

413 institutions reported holding Madrigal Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 202 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MDGLMadrigal Pharmaceuticals, Inc.Follow MDGL — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 10.0B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 10 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

413 institutions held —% of the shares. Across filers that reported both quarters, shares held changed -0.8%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	413	24	-0.8%	135	65	124	36
Mar 26	375	24	+1.9%	114	50	116	52
Dec 25	384	24	-0.2%	127	62	110	31
Sep 25	341	23	+0.2%	96	72	100	31
Jun 25	303	24	-1.0%	94	31	98	45
Mar 25	316	24	+3.6%	96	63	78	28
Dec 24	278	23	+0.7%	84	49	71	33
Sep 24	253	23	-1.9%	74	38	75	41

Madrigal Pharmaceuticals, Inc. — questions

Who owns Madrigal Pharmaceuticals, Inc. stock?: 413 institutions reported Madrigal Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BAKER BROS. ADVISORS LP (9.3%), RTW INVESTMENTS, LP (8.6%), Jupiter Topco LLC (8.4%).
Are Madrigal Pharmaceuticals, Inc. insiders buying or selling?: 202 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Madrigal Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.